BioTelemetry Inc. (NASDAQ:BEAT) shot up 3.2% on Wednesday . The company traded as high as $16.69 and last traded at $16.60, with a volume of 140,916 shares trading hands. The stock had previously closed at $16.08.

Separately, Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a research note on Tuesday, April 19th.

The stock has a market capitalization of $462.76 million and a price-to-earnings ratio of 42.00. The firm’s 50 day moving average price is $16.28 and its 200 day moving average price is $13.01.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.10. During the same quarter in the prior year, the company earned $0.06 EPS. The firm earned $48.60 million during the quarter, compared to analyst estimates of $46.54 million. The business’s revenue was up 12.0% on a year-over-year basis. Equities analysts predict that BioTelemetry Inc. will post $0.71 EPS for the current fiscal year.

A number of large investors recently made changes to their positions in the stock. 1492 Capital Management LLC boosted its stake in shares of BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock worth $3,758,000 after buying an additional 32,932 shares during the period. Royce & Associates LLC boosted its stake in shares of BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock worth $7,086,000 after buying an additional 306,700 shares during the period. Wells Fargo & Company MN boosted its stake in shares of BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock worth $11,612,000 after buying an additional 119,328 shares during the period. Gabelli Funds LLC bought a new stake in shares of BioTelemetry during the fourth quarter worth approximately $1,190,000. Finally, Teton Advisors Inc. boosted its stake in shares of BioTelemetry by 26.3% in the fourth quarter. Teton Advisors Inc. now owns 135,100 shares of the company’s stock worth $1,578,000 after buying an additional 28,100 shares during the period.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.